Exploring Legend Biotech Corporation (LEGN) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind Legend Biotech (LEGN), and what motivates their investment decisions? As of December 31, 2024, a total of 457 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 118,808,868 shares. With the share price experiencing a 32.68% decline from $50.12 on April 16, 2024, to $33.74 as of April 15, 2025, understanding the investor landscape becomes crucial. Are you curious to discover which firms hold the largest stakes and what their recent trading activities reveal about the future of LEGN?

Legend Biotech Corporation (LEGN) Who Invests in Legend Biotech Corporation (LEGN) and Why?

Understanding the investor profile of Legend Biotech Corporation (LEGN) provides valuable insights into the market's perception of the company. By examining the types of investors, their motivations, and typical investment strategies, a clearer picture emerges of why individuals and institutions are drawn to LEGN.

Key Investor Types:

The investor base of Legend Biotech Corporation is diverse, encompassing retail investors, institutional investors, and hedge funds. Each group brings its own investment horizon, risk tolerance, and expectations.

• Retail Investors: These individual investors often have varying levels of financial knowledge and invest for long-term growth or short-term gains.
• Institutional Investors: These include mutual funds, pension funds, insurance companies, and endowments that manage large sums of money on behalf of others.
• Hedge Funds: These are investment partnerships that use pooled funds and employ different strategies to earn active return, or alpha, for their investors.

Investment Motivations:

Several factors attract investors to Legend Biotech Corporation (LEGN). These motivations often align with the company's growth prospects, market position, and potential for innovation in the biotechnology sector.

• Growth Prospects: Investors are often drawn to LEGN due to its potential for significant growth in the biotechnology industry, particularly in the field of cell therapy.
• Market Position: A strong market position and strategic partnerships can make LEGN an attractive investment.
• Innovation: The company's focus on innovative therapies and technologies can appeal to investors looking for groundbreaking advancements in healthcare.

Investment Strategies:

Investors in Legend Biotech Corporation (LEGN) employ a variety of strategies depending on their investment goals and risk tolerance.

• Long-Term Holding: Some investors adopt a long-term holding strategy, maintaining their positions for several years to benefit from the company's long-term growth.
• Short-Term Trading: Other investors engage in short-term trading, seeking to profit from short-term price fluctuations.
• Value Investing: Value investors may see LEGN as undervalued by the market and invest with the expectation that the stock price will eventually reflect its intrinsic value.

Examining the ownership structure can reveal which institutions have the largest stakes in Legend Biotech Corporation. For instance, looking at the top institutional holders and their positions can offer insights into the confidence that major players have in the company's future.

While specific recent ownership percentages may fluctuate, regulatory filings such as 13F filings provide updated information on institutional ownership. These filings are crucial for understanding the changing dynamics of investor interest in LEGN.

For more insights into Legend Biotech Corporation, you might find this resource helpful: Legend Biotech Corporation (LEGN): History, Ownership, Mission, How It Works & Makes Money

Legend Biotech Corporation (LEGN) Institutional Ownership and Major Shareholders of Legend Biotech Corporation (LEGN)

Institutional ownership in Legend Biotech Corporation (LEGN) reflects the extent to which large financial organizations, such as mutual funds, hedge funds, and insurance companies, hold the company's shares. As of April 2025, 457 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 118,808,868 shares.

The percentage of Legend Biotech Corporation (LEGN) stock held by various investor types is approximately 27.05% by institutional shareholders and 72.95% by retail investors.

Here's a list of the top institutional investors in Legend Biotech Corporation (LEGN) and their approximate shareholdings:

• Fmr Llc: 7.32%
• RA Capital Management, L.P.: 4.09%
• Price T Rowe Associates Inc: 3.71%
• Hillhouse Capital Advisors, Ltd: 3.26%
• Westfield Capital Management Co Lp: 3.11%
• BlackRock, Inc.: 2.51%
• Suvretta Capital Management, Llc: 1.90%
• Invesco Ltd.
• Braidwell Lp

Other significant shareholders include:

• GenScript Biotech Corporation: 47.51%
• AquaPoint L.P.: 8.25%

Recent trading activities show institutions adding and decreasing their positions in LEGN stock. For example, Wellington Management Group LLP increased their shares by 4.1% in the first quarter of 2025, while SG Americas Securities LLC increased their shares by 661.0%.

Here's a summary of recent institutional buying and selling activity:

Institutional investors can significantly influence a company's stock price and strategy. Their buying and selling patterns can create volatility, and their influence can impact management decisions. Legend Biotech's stock has experienced some turbulence recently, hitting a 52-week low of $30.16 on April 7, 2025, but analysts suggest it may be undervalued with price targets ranging from $53 to $95.

Despite recent market challenges, Legend Biotech reported strong revenue growth of 120% over the last twelve months and exceeded analyst expectations in the fourth quarter of 2024, with revenue reaching $186.52 million. The company's management remains confident in continued strong performance for 2025, driven by the success of CARVYKTI, which generated approximately $963 million in net trade sales for the full year 2024.

To gain further insights into Legend Biotech Corporation's values, explore: Mission Statement, Vision, & Core Values of Legend Biotech Corporation (LEGN).

Legend Biotech Corporation (LEGN) Key Investors and Their Impact on Legend Biotech Corporation (LEGN)

Understanding the investor profile of Legend Biotech Corporation (LEGN) provides valuable insights into the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock performance through their holdings and actions.

While specific, real-time details on all current investors and their recent moves are often proprietary, we can look at the general types of investors and their potential impact, along with examples of significant investors based on available information.

Institutional investors, mutual funds, and hedge funds are common types of investors in Legend Biotech Corporation (LEGN). These entities often hold substantial shares and can influence the company's stock price and strategic decisions. Highlighting specific major investors can be challenging due to the dynamic nature of stock ownership and reporting requirements.

Here are some potential types of investors and their possible influence:

• Institutional Investors: These include pension funds, insurance companies, and endowments. They typically invest for long-term growth and stability. Their large holdings can provide a stable base for the stock.
• Mutual Funds: These funds pool money from many investors to invest in a diversified portfolio. Their investment decisions can drive significant trading volume in Legend Biotech Corporation (LEGN) shares.
• Hedge Funds: These are often more actively managed and may take more aggressive positions. Their activities can lead to short-term volatility in the stock price.
• Activist Investors: While not always present, activist investors take large positions in a company and then push for changes in management or strategy. Their involvement can lead to significant shifts in company direction.

The influence of these investors can manifest in several ways:

• Stock Price Movements: Large purchases or sales by major investors can cause significant fluctuations in Legend Biotech Corporation (LEGN)'s stock price.
• Corporate Governance: Major shareholders have the power to influence board elections and key corporate decisions.
• Strategic Direction: Investors can publicly or privately advocate for specific strategic changes, such as mergers, acquisitions, or restructuring.

Analyzing the ownership structure and tracking the moves of significant investors are crucial for understanding the potential future direction and stability of Legend Biotech Corporation (LEGN). However, without access to real-time proprietary data, pinpointing exact current holdings and recent transactions remains challenging.

For more insights into Legend Biotech Corporation (LEGN), you might find this resource helpful: Legend Biotech Corporation (LEGN): History, Ownership, Mission, How It Works & Makes Money

Legend Biotech Corporation (LEGN) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to ownership changes is crucial for assessing the future trajectory of Legend Biotech Corporation (LEGN). Recent activity by major shareholders and analyst perspectives provide valuable insights into the company's potential.

Investor Sentiment: Investor sentiment towards Legend Biotech Corporation (LEGN) appears mixed, influenced by factors such as clinical trial outcomes, regulatory approvals, and market conditions. Recent news and filings offer a glimpse into how major shareholders are reacting to these developments.

Based on recent reports, institutional investors continue to hold a significant portion of Legend Biotech Corporation (LEGN)'s shares. For instance, Viking Global Investors LP held 11,347,737 shares as of December 31, 2024.

Here's a glimpse into some major institutional shareholders:

• Viking Global Investors LP: 11,347,737 shares
• FMR LLC: 7,798,294 shares
• RA Capital Management, L.P.: 6,567,783 shares

Institutional ownership is a critical factor, with institutions holding approximately 57.30% of the company's shares. T. Rowe Price Associates Inc. is another notable institutional investor, holding 4,794,889 shares. These large positions can significantly influence the stock's stability and trading volume.

Recent Market Reactions: The stock market's response to changes in Legend Biotech Corporation (LEGN)'s ownership or large investor moves can be indicative of the company's perceived health and prospects. For example, significant purchases or sales by institutional investors often trigger corresponding movements in the stock price.

Legend Biotech Corporation (LEGN) has experienced notable market reactions following key announcements and investor activities. The stock's performance is closely tied to developments in its clinical programs and regulatory milestones. Recent data indicates a fluctuating market response, reflecting the inherent risks and opportunities in the biotechnology sector.

Analyst Perspectives: Analysts' insights play a vital role in shaping investor perception of Legend Biotech Corporation (LEGN). These experts evaluate the company's financial performance, pipeline potential, and competitive landscape to provide recommendations and price targets.

Analysts' perspectives on Legend Biotech Corporation (LEGN) vary, reflecting the complexities of the biotechnology industry. Some analysts highlight the company's innovative cell therapy platform and promising clinical results, while others express concerns about regulatory hurdles and market competition. The consensus view often balances these factors, resulting in a range of ratings from 'Buy' to 'Hold.'

Here’s a snapshot of analyst ratings and price targets:

• Consensus Rating: Hold
• Average Price Target: Varies among analysts, reflecting different valuation methodologies and outlooks

To delve deeper into Legend Biotech Corporation (LEGN)'s background, mission, and ownership structure, explore this resource: Legend Biotech Corporation (LEGN): History, Ownership, Mission, How It Works & Makes Money

Below is a table summarizing key financial data and market capitalization details for Legend Biotech Corporation (LEGN) as of 2024:

Understanding these elements provides a comprehensive view of Legend Biotech Corporation (LEGN)'s position in the market and the factors influencing investor decisions.

Legend Biotech Corporation (LEGN)'s financial performance reflects its focus on research and development, particularly in the field of cell therapies. While the company reported a net loss of $733.5 million for the year 2024, its revenue reached $239.4 million, indicating growing commercial activities. The company's substantial cash reserves of $1.1 billion as of December 31, 2024, provide a buffer for ongoing operations and future investments.

Legend Biotech Corporation (LEGN) faces competition from other biotechnology firms in the cell therapy space. These competitors are also developing innovative treatments for various cancers and autoimmune diseases. The competitive landscape is characterized by:

• Intense research and development efforts
• Stringent regulatory requirements
• Dynamic market conditions

Legend Biotech Corporation (LEGN)'s ability to navigate these challenges and maintain its competitive edge will depend on its ability to:

• Secure regulatory approvals for its product candidates
• Expand its commercial reach
• Forge strategic partnerships